肝癌患者血清中腫瘤特異性生長因子水平與臨床病理特征及預后的關系_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 程黎

重慶三峽中心醫院肝膽外科（重慶萬州 404100）;

Corresponding?author：

程黎, Email: cqchengli@163.com

Keywords：

肝細胞癌; 腫瘤特異性生長因子; 臨床病理特征; 預后

DOI：

10.7507/1007-9424.20150260

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的探討肝細胞癌（簡稱“肝癌”）患者血清中腫瘤特異性生長因子（TSGF）水平與患者臨床病理特征及預后的關系。方法選取2010年1月至2013年12月期間我院收治的76例行手術治療的肝癌患者（肝癌組）和45例正常健康體檢者（對照組），比較2組間血清TSGF水平，并觀察血清TSGF水平與肝癌患者的臨床病理特征和預后之間的關系。結果肝癌組血清TSGF水平為（86.25±10.52）U/mL，表達陽性率為76.32%（58/76），均明顯高于對照組的（25.32±6.54）U/mL和6.67%（3/45），差異有統計學意義（t=35.019，P＜0.001；χ²=52.097，P＜0.001）。血清TSGF水平與肝癌患者有無癌栓、TNM分期、組織分化程度、有無肝硬變有關（均P＜0.05）。血清TSGF水平陽性表達者3年總生存率為55.0%，明顯低于陰性表達者的3年總生存率（85.7%），兩者之間比較差異有統計學意義（χ²=4.502，P=0.034）。結論 TSGF在肝癌患者血清中高表達，與有無癌栓、TNM分期、組織分化程度、有無肝硬變有關，且其表達高者預后差，有助于肝癌的診斷和預后評價。

Citation： 程黎. 肝癌患者血清中腫瘤特異性生長因子水平與臨床病理特征及預后的關系. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(8): 995-997. doi: 10.7507/1007-9424.20150260 Copy

1.	Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet, 2012, 379(9822):1245-1255.
2.	Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2):69-90.
3.	Lu W, Dong J, Huang Z, et al. Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma under-going curative resection:Okuda, CLIP, TNM and CUPI. J Gastroen-terol Hepatol, 2008, 23(12):1874-1878.
4.	王君哲, 牟君成, 范慧, 等.血清腫瘤相關物質檢測在惡性腫瘤診斷中的應用價值.重慶醫學, 2010, 39(11):1418-1419.
5.	陳芳華, 駱曦, 饒萬楷.惡性腫瘤特異性生長因子對惡性腫瘤的診斷價值.國際檢驗醫學雜志, 2011, 32(11):1183-1184, 1186.
6.	周琦, 張瓊, 魏來.血清甲胎蛋白、腫瘤相關物質和癌胚抗原對原發性肝癌的鑒別診斷.世界華人消化雜志, 2010, 18(18):1936-1939.
7.	康從利, 徐日, 徐風亮, 等.血清腫瘤標志物的聯合動態檢測在原發性肝癌診斷中的價值.腫瘤研究與臨床, 2014, 26(8):531-534, 538.
8.	趙建軍, 閻濤, 黃振, 等.中國肝細胞癌患者最佳分期系統探討.中華醫學雜志, 2014, 94(12):903-907.
9.	Wang G, Qin Y, Zhang J, et al. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer. Int J Mol Sci, 2014, 15(6):9546-9565.
10.	Chen Y, Gao SG, Chen JM, et al. Serum CA242, CA199, CA125, CEA, and TSGF are biomarkers for the efficacy and prognosis of cryoablation in pancreatic cancer patients. Cell Biochem Biophys, 2014 Dec 9.[Epub ahead of print].
11.	孟冬婭, 胡曉芳, 高洪福, 等.檢測血清VEGF、CEA、TSGF在腫瘤中的臨床意義.中國現代醫學雜志, 2004, 14(1):117-118.
12.	原曉勇, 吳斌.血清TSGF在乳腺癌中的研究現狀.現代臨床醫學, 2011, 37(2):83-84.
13.	Bast RC, Ravdin P, Hayes DF, et al. 2000 update of recommenda-tions for the use of tumor markers in breast and colorectal cancer:clinical practice guidelines of the American Society of Clinical Onco-logy. J Clin Oncol, 2001, 19(6):1865-1878.
14.	王建俊, 王金鵬.血清TSGF和CA199聯檢對肝硬化的診斷價值的研究.醫學檢驗與臨床, 2011, 22(4):18-19.
15.	Karaman B, Battal B, Sari S, et al. Hepatocellular carcinoma review:current treatment, and evidence-based medicine. World J Gastroen-terol, 2014, 20(47):18059-18060.

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet, 2012, 379(9822):1245-1255.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2):69-90.
3. Lu W, Dong J, Huang Z, et al. Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma under-going curative resection:Okuda, CLIP, TNM and CUPI. J Gastroen-terol Hepatol, 2008, 23(12):1874-1878.
4. 王君哲, 牟君成, 范慧, 等.血清腫瘤相關物質檢測在惡性腫瘤診斷中的應用價值.重慶醫學, 2010, 39(11):1418-1419.
5. 陳芳華, 駱曦, 饒萬楷.惡性腫瘤特異性生長因子對惡性腫瘤的診斷價值.國際檢驗醫學雜志, 2011, 32(11):1183-1184, 1186.
6. 周琦, 張瓊, 魏來.血清甲胎蛋白、腫瘤相關物質和癌胚抗原對原發性肝癌的鑒別診斷.世界華人消化雜志, 2010, 18(18):1936-1939.
7. 康從利, 徐日, 徐風亮, 等.血清腫瘤標志物的聯合動態檢測在原發性肝癌診斷中的價值.腫瘤研究與臨床, 2014, 26(8):531-534, 538.
8. 趙建軍, 閻濤, 黃振, 等.中國肝細胞癌患者最佳分期系統探討.中華醫學雜志, 2014, 94(12):903-907.
9. Wang G, Qin Y, Zhang J, et al. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer. Int J Mol Sci, 2014, 15(6):9546-9565.
10. Chen Y, Gao SG, Chen JM, et al. Serum CA242, CA199, CA125, CEA, and TSGF are biomarkers for the efficacy and prognosis of cryoablation in pancreatic cancer patients. Cell Biochem Biophys, 2014 Dec 9.[Epub ahead of print].
11. 孟冬婭, 胡曉芳, 高洪福, 等.檢測血清VEGF、CEA、TSGF在腫瘤中的臨床意義.中國現代醫學雜志, 2004, 14(1):117-118.
12. 原曉勇, 吳斌.血清TSGF在乳腺癌中的研究現狀.現代臨床醫學, 2011, 37(2):83-84.
13. Bast RC, Ravdin P, Hayes DF, et al. 2000 update of recommenda-tions for the use of tumor markers in breast and colorectal cancer:clinical practice guidelines of the American Society of Clinical Onco-logy. J Clin Oncol, 2001, 19(6):1865-1878.
14. 王建俊, 王金鵬.血清TSGF和CA199聯檢對肝硬化的診斷價值的研究.醫學檢驗與臨床, 2011, 22(4):18-19.
15. Karaman B, Battal B, Sari S, et al. Hepatocellular carcinoma review:current treatment, and evidence-based medicine. World J Gastroen-terol, 2014, 20(47):18059-18060.

Previous Article
暴飲暴食致急性胃擴張并胃壞死破裂1例報道
Next Article
腹壁復發切口疝的微創治療體會

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

肝癌患者血清中腫瘤特異性生長因子水平與臨床病理特征及預后的關系

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content